Akums drugs & pharma has secured European GMP certificates for its two manufacturing facilities located at Haridwar, Uttarakhand, marking a significant regulatory milestone for the pharmaceutical company. The certification was granted by the Bulgarian Drug Agency (BDA) and represents both a renewal and a fresh approval for the company's manufacturing capabilities.

Certification Details

The European GMP certificates cover two distinct facilities with different approval statuses:

Both certifications are valid for a period of three years, extending until October 2028, providing the company with a stable regulatory framework for European market operations.

Market Access and Business Impact

The European GMP accreditations will enable Akums Drugs and Pharmaceuticals Limited to expand its market reach significantly. The certifications provide access to:

• EU regulated markets
• Several other international markets that follow EU-GMP regulations
• New business opportunities from European Union countries

The company has already positioned itself to leverage these approvals, with Plant 2 designated to service the European CDMO contract that was signed in December 2024.

Manufacturing Capabilities

With the new certifications, each facility is authorized for specific product categories:

Plant 1 Authorization:

• Tablets manufacturing and supply
• Hard gelatine capsules production
• Sachet dosage forms

Plant 2 Authorization:

• Oral liquid formulations manufacturing
• Supply capabilities for EU countries
• Service delivery for European CDMO operations

Regulatory Compliance

The company disclosed this development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating its commitment to transparency and regulatory compliance. The Bulgarian Drug Agency serves as the regulatory authority for these European GMP certifications, ensuring adherence to stringent European pharmaceutical manufacturing standards.

These certifications represent a strategic advancement for Akums Drugs and Pharmaceuticals Limited, positioning the company to capitalize on European market opportunities while maintaining compliance with international pharmaceutical manufacturing regulations.

Ruby Qc Investment Holdings Pte Ltd, a Singapore-based investment entity, has completed the disposal of its entire shareholding in Akums Drugs & Pharma through a block deal transaction. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, on December 22, 2025.

Transaction Details

The disposal involved the complete divestment of Ruby Qc Investment Holdings' stake in the pharmaceutical company. The transaction details are presented below:

Shareholding Pattern Changes

The disposal represents a complete exit by Ruby Qc Investment Holdings from Akums Drugs & Pharma. The shareholding pattern changes are detailed below:

Regulatory Compliance

The disclosure was filed with both the National Stock Exchange of India Limited and BSE Limited, where Akums Drugs & Pharma shares are listed. Ruby Qc Investment Holdings Pte Ltd, incorporated in Singapore with registration number 201905580M, completed all regulatory requirements under SEBI's substantial acquisition regulations.

Company Information

Ruby Qc Investment Holdings Pte Ltd is registered at 55 Paterson Road, Singapore 238550, with Abrar Mir serving as Director. The entity has been operating as an investment holding company incorporated in the Republic of Singapore.

The transaction marks the complete exit of the Singapore-based investment entity from the Indian pharmaceutical company, with no remaining shareholding or encumbrances following the December 22, 2025 block deal execution.